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Abstract
Background: Many studies have attempted to determine the "best" anaesthetic technique for
neurosurgical procedures in patients without intracranial hypertension. So far, no study comparing
intravenous (IA) with volatile-based neuroanaesthesia (VA) has been able to demonstrate major
outcome differences nor a superiority of one of the two strategies in patients undergoing elective
supratentorial neurosurgery. Therefore, current practice varies and includes the use of either
volatile or intravenous anaesthetics in addition to narcotics. Actually the choice of the
anaestesiological strategy depends only on the anaesthetists' preferences or institutional policies.
This trial, named NeuroMorfeo, aims to assess the equivalence between volatile and intravenous
anaesthetics for neurosurgical procedures.
Methods/Design: NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based
on an equivalence design. Patients aged between 18 and 75 years, scheduled for elective craniotomy
for supratentorial lesion without signs of intracranial hypertension, in good physical state (ASA I-
III) and Glasgow Coma Scale (GCS) equal to 15, are randomly assigned to one of three
anaesthesiological strategies (two VA arms, sevoflurane + fentanyl or sevoflurane + remifentanil,
and one IA, propofol + remifentanil). The equivalence between intravenous and volatile-based
neuroanaesthesia will be evaluated by comparing the intervals required to reach, after anaesthesia
discontinuation, a modified Aldrete score ≥ 9 (primary end-point). Two statistical comparisons
have been planned:
1) sevoflurane + fentanyl vs. propofol + remifentanil;
2) sevoflurane + remifentanil vs. propofol + remifentanil.
Secondary end-points include: an assessment of neurovegetative stress based on (a) measurement
of urinary catecholamines and plasma and urinary cortisol and (b) estimate of sympathetic/
parasympathetic balance by power spectrum analyses of electrocardiographic tracings recorded
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during anaesthesia; intraoperative adverse events; evaluation of surgical field; postoperative adverse
events; patient's satisfaction and analysis of costs.
411 patients will be recruited in 14 Italian centers during an 18-month period.
Discussion: We presented the development phase of this anaesthesiological on-going trial. The
recruitment started December 4th, 2007 and up to 4th, December 2008, 314 patients have been
enrolled.
Background
Anaesthesia for neurosurgical procedures should ideally
provide optimal surgical conditions while maintaining
appropriate cerebral oxygen supply and stable systemic
haemodynamics. Rapid emergence from anaesthesia is
also desirable to allow a quick neurological examination
at the end of procedure.
Over the years, several studies have demonstrated that in
patient with intracranial hypertension the best strategy is
based on intravenous anaesthesia for its beneficial cere-
bral haemodynamic effects, for its "neuroprotective" role
and for its action on cerebral metabolism [1].
On the other hand no studies have been able to determine
the "best" anaesthetic technique for neurosurgical proce-
dures in patients without signs of cerebral hypertension.
The choice of volatile or intravenous strategy is still
actively debated [2].
Current practice seems to vary and includes the use of
either volatile or intravenous anaesthetics in addition to
various narcotics [3]. The most frequently administered
anaesthetics during neurosurgical procedures are either
propofol-opioid or sevoflurane-opioid [4]. Inhaled agents
are preferred by some neuroanaesthetists because of the
ease of their administration, the availability of end-tidal
agent monitoring and lack of evidence of outcome com-
pared with intravenous hypnotics. Other anaesthetists
prefer, on the other hand, intravenous anaesthesia.
The drugs studied in this neuroanaesthesia trial include:
Sevoflurane
Sevoflurane is a halogenated inhalational anaesthetic
agent administered by vaporization and used in induction
and maintenance of anaesthesia. Minimum Alveolar Con-
centration (MAC) in oxygen mixture for a 40 years old
adult is 2.1%; MAC decreases with age. Sevoflurane has a
direct vasodilator effect that increase cerebral blood flow
(CBF) while reduce cerebral metabolic rate (CMRO2).
CBF normalizes approximately 3 hours after the initial
exposure to 1.3 MAC of anaesthetic.
Propofol
Propofol is an intravenous sedative-hypnotic agent used
during anaesthesia induction and maintenance. Intrave-
nous injection of a therapeutic dose of propofol induces
hypnosis usually within 40 seconds from the start of injec-
tion, the interval request for one arm-brain circulation.
Steady-state propofol blood concentrations are generally
proportional to infusion rates. Propofol has many of the
properties of an ideal agent for neuroanaesthesia, with
beneficial cerebral haemodynamic effects reducing CBF,
favourable pharmacokinetics and high-quality recovery
profile despite prolonged duration of infusion. It reduces
CMRO2 to a similar extent as Sevoflurane [1].
Opioids that are usually associated with intravenous and
volatile anaesthesia are remifentanil and fentanyl.
Remifentanil
Remifentanil is an antagonist of opioid μ-receptor and it
has a peculiar pharmacokinetic property due to its metab-
olism mediated by a non specific esterase with rapid onset
and termination effects, independently by the duration of
administration. It's commonly used as analgesic for
induction and maintenance of anaesthesia as synergistic
agent with other anaesthetics.
Fentanyl
Fentanyl is an opioid analgesic. It interacts predominately
with the opioid μ-receptor and exerts its principal phar-
macologic effects on the central nervous system. Its pri-
mary actions of therapeutic value are analgesia and
sedation. Fentanyl may increase the patient's tolerance for
pain. Its analgesic activity is, most likely, due to its conver-
sion to morphine.
Few studies compared propofol-based anaesthesia with
other types of anaesthesia in neurosurgical patients. Todd
[2] compared propofol/fentanyl with nitrous oxide/fenta-
nyl and isoflurane/nitrous oxide in 121 patients undergo-
ing craniotomy for supratentorial mass lesions. There
were minor differences in adverse effects, but no signifi-
cant differences in neurological outcome. Nitrous oxide/
fentanyl patients had more hypotension during induction
and more post-operative vomiting, but were quicker to
awaken in recovery. Isoflurane/nitrous oxide patients hadTrials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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more tachycardia during induction, higher ICP prior to
dural opening and longer emergence times. Finally, pro-
pofol/fentanyl patients had less haemodynamic instabil-
ity during induction and less postoperative vomiting, but
were slower than the nitrous oxide/fentanyl patients to
wake-up. Recently Magni [5] evaluated emergence time
and early postoperative cognitive function in patients
who received either a volatile-based anaesthetic or a total
intravenous anaesthetic. The authors demonstrated no
differences in intraoperative brain volume, emergence
time, early postoperative cognitive abilities, or the inci-
dences of postoperative shivering, pain, or nausea and
vomiting. However, both intraoperative hypertensive and
hypotensive episodes were more common in patients
anaesthetized with propofol and remifentanil.
Based on current evidence, carefully administered anaes-
thesia with any of a variety of agents will result in a similar
outcome. To evaluate the "anaesthesia quality", we must
therefore use surrogate combined endpoints. A score used
in anaesthesia is the modified Aldrete score [6] that ana-
lyzes motility, respiration and oxygenation, cardiovascu-
lar stability and consciousness. The sum of the scores
ranges between 0 and 10 and a adequate score at the emer-
gence from anaesthesia is ≥ 9.
In some recent articles the modified Aldrete score has
been applied to patients anaesthetized for a craniotomy.
Balakrishnan [7] compared the effects of remifentanil ver-
sus fentanyl during surgery for intracranial space-occupy-
ing lesions. Anaesthesia maintenance doses of isoflurane,
nitrous oxide, and opioid were at the anaesthesiologist's
discretion for both groups. The percentage of patients
with a normal recovery score (alert or arousable to quiet
voice, oriented, able to follow commands, motor function
unchanged from their preoperative evaluation, not agi-
tated, and had modified Aldrete Scores of 9–10) at 10 min
after surgery was significantly higher for remifentanil
(45% vs. 18%; P = 0.005). By 20 min, the difference
between groups was not maintained (P = 0.27).
Talke [8] compared three anaesthetic techniques (inhala-
tion, intravenous, mixed) in patients undergoing craniot-
omy for supratentorial intracranial surgery. None of the
recovery event times (open eyes, extubation, follow com-
mands, oriented, Aldrete score) or psychomotor test per-
formance differed significantly. Mean interval to obtain
an Aldrete score ≥ 9 was 15 minutes in all three groups.
This prospective, randomized clinical study found that the
three anaesthetics did not differ in intra- or postoperative
haemodynamic stability or early postoperative recovery
variables.
Boztug [9] investigated the role of using the bispectral
index (BIS) in recovery from anaesthesia and altering drug
administration in patients undergoing craniotomy.
Times to first spontaneous breathing, eye opening, and
extubation (P = 0.035, P = 0.001, and P = 0.0001, respec-
tively) were significantly shorter in the BIS-guided group.
Time to an Aldrete score of 9–10 (24 ± 6 vs. 27 ± 6 min-
utes) and adequate neurological assessment was similar
between the groups.
Del Gaudio [10] compared the use of remifentanil and
fentanyl during elective supratentorial craniotomy in a
target controlled infusion (TCI)-propofol anaesthesia reg-
imen and evaluated the quality of recovery from anaesthe-
sia. Intervals for an Aldrete score of 9–10 were respectively
about 8.6 ± 1.6 minutes and 14.6 ± 2.6 minutes.
Lauta, in a preliminary report presented at the 2003
SNACC meeting [11], demonstrated similar times to an
Aldrete  ≥ 9 (median 5 minutes) for both volatile and
intravenous anaesthesia.
Since the impact of both anaesthesiological strategies on
the outcome of neurosurgical procedures is similar, we
decided to compare different endpoints such as time to
reach consciousness. So far, in patients undergoing elec-
tive supratentorial neurosurgery, no study comparing
intravenous with volatile-based neuroanaesthesia has
been able to demonstrate neither major outcome differ-
ences nor a superiority of one of the two strategies [3,5].
Rather contrasting results has been published concerning
secondary anaesthesia effects like intraoperative brain vol-
ume, early postoperative cognitive ability, incidence of
postoperative shivering, pain, nausea and vomiting [8].
This paper presents the design of the NeuroMorfeo study,
an open trial comparing volatile versus intravenous anaes-
thesia strategies in patients undergoing elective supraten-
torial neurosurgery.
Methods
The NeuroMorfeo study is a multicenter randomized,
open label, controlled trial, with equivalence design [12],
evaluating volatile anaesthesia vs. intravenous anaesthe-
sia strategies in patients undergoing supratentorial elec-
tive neurosurgery. Enrolment criteria, evaluated in all
patients during a routine preoperative assessment and
physical examination, are summarized in the appendix.
Before anaesthesia induction, patient is premedicated
with Midazolam (5 mg IV). An isotonic crystalloid saline
solution (7–10 mL/kg) is infused through a peripheral
intravenous catheter and a second line is inserted for drugTrials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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administration. All patients are preoxygenated for 3 min-
utes with a reservoir bag in 100% O2.
In all patients, anaesthesia is induced with:
- Propofol (2–3 mg/kg IV),
- Fentanyl (2 to 4 μg/kg IV) in the group 1 and remifen-
tanil (0.25 μg/kg/min IV infused for 3 minutes before
induction) in groups 2 and 3.
- Cisatracurium (0.1–0.2 mg/kg IV).
After intubation of the trachea, patients are mechanically
ventilated with an inspired mixture of air and oxygen
(2:1). Ventilation, using a closed breathing system (fresh
gas flow of 0.75 L/min oxygen and 1.5 L/min air during
anaesthesia), is adjusted to achieve an end-tidal carbon
dioxide of 30–35 mmHg. No local anaesthesia is allowed.
Therefore anaesthesia is maintained according to one of
these three different study groups:
1. (IF) sevoflurane + fentanyl: sevoflurane is main-
tained in a 0.75 to 1.25 MAC range and fentanyl (2–3
μg/kg/hr or 0.7 μg/kg boluses). Just before incision of
the scalp, fentanyl (1–2 μg/kg/hr) can be supple-
mented, if necessary;
2. (IR) sevoflurane + remifentanil: sevoflurane is main-
tained in a 0.75 to 1.25 MAC range and remifentanil
(0.05–0.25 μg/kg/min reduced to 0.05–0.1 μg/kg/min
after dural opening). Just before incision of the scalp,
remifentanil can be supplemented, if necessary;
3. (ER) propofol + remifentanil: propofol is maintained
with continuous infusion at 10 mg/kg/h for the first
10 minutes, then reduced to 8 mg/kg/h for the follow-
ing 10 minutes and reduced to 6 mg/kg/h thereafter
and remifentanil 0.05–0.25 μg/kg/min reduced to
0.05–0.1 μg/kg/min after dural opening. Just before
incision of the scalp, remifentanil could be supple-
mented, if necessary.
During surgery all patients are paralyzed with cisatracu-
rium (0.1 mg/kg/h), stopped once the bone flap is
secured.
At the end of surgery, residual neuromuscular blockade
will be antagonized with neostigmine 2.5 mg and atro-
pine 1 mg.
Sevoflurane and propofol infusions are reduced once the
bone flap is secured and stopped at skin dressing. Fenta-
nyl is stopped at skin dressing and remifentanil reduced at
skin dressing by 30% every 3–4 minutes.
Analgesia is started before bone flap repositioning with
paracetamol and morphine 0.03–0.1 mg/kg IV in
remifentanil groups.
Patients are randomly assigned to one of these three strat-
egies with equal probability. Balanced randomization is
maintained at each clinical site using a stratified randomi-
zation scheme. Patients are randomized the day before
surgery, once the patient has provided written informed
consent and satisfied all the study eligibility criteria. The
patient identification and treatment allocation are pro-
vided by the central randomization service through an
interactive voice response system (IVRS). After randomi-
zation a confirmation e-mail with randomization details
is automatically sent to the center. In order to minimize
the possibility of bias in reporting and assessing primary
and secondary endpoints, the trial adopted a PROBE
design (Prospective Randomized Open trial with Blinded
Evaluation of outcomes).
The primary end point is the post-anaesthesia recovery,
assessed as the interval required to reach an Aldrete score
≥ 9 [6]. The Aldrete Recovery Score, which sets the stand-
ards for post-anaesthesia discharge criteria for patients, is
a score (range 0–10, Table 1) used by doctors and nurses
in the operating rooms. Interval (minutes; seconds)
required from patient extubation to reach a modified
Aldrete score ≥ 9 is evaluated in each patient.
The following comparisons are planned:
- Sevoflurane + remifentanil versus propofol + remifentanil;
- Sevoflurane + fentanyl versus propofol + remifentanil [7,10].
The Aldrete score is assessed by a trained anaesthesiolo-
gist, blinded to allocation treatment group. Every 30–60
seconds the anaesthesiologist checks the patients' activity
(ability to move extremities), respiration (ability to cough
and breath), circulation (level of blood pressure com-
pared to patient personal baseline), consciousness (ability
to keep himself awake), colour (level of peripheral oxygen
saturation).
Every anaesthesiologist involved in the evaluation of the
score has been trained and certified with a dedicated soft-
ware course developed to use the Aldrete score.
Secondary end points are:
1. Anaesthesia-related neurovegetative stress evaluation
through the measurement of:Trials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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Table 1: The Aldrete Score
ACTIVITY 2 = Able to move spontaneously or on command 4 extremities
1 = Able to move voluntarily or on command 2 extremities
0 = Unable to move any extremities
RESPIRATION 2 = Able to deep breath and cough freely
1 = Dyspnea, shallow or limited breathing
0 = Apneic
CIRCULATION 2 = BP + 20 mmHg of pre-sedation level
1 = BP + 20–50 mmHg of pre-sedation level
0 = BP + 50 mmHg of pre-sedation level
CONSCIOUSNESS 2 = Fully awake
1 = Arousable on calling
0 = Not responding
SKIN COLOR 2 = Normal
1 = Pale, dusky, blotchy, jaundiced, other
0 = Cyanotic
Scheme of blood and urine samples for stress biomarkers (cortisol and catecholamines) Figure 1
Scheme of blood and urine samples for stress biomarkers (cortisol and catecholamines). For each patient samples 
are collected before the induction, during surgical procedure and after awakening to evaluate within-patient changes.Trials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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a) Haemodynamic stability.
b) Stress biomarkers (cortisol and catecholamines)
[13]. Blood and urine samples are collected before the
induction, during surgical procedure and after awak-
ening to evaluate within-patient changes in biomark-
ers (as shown in figure 1). [14-18]
c) Cardiac autonomic function (dynamic analysis of
the ECG)[19,20] Cardiac autonomic function tracings
and biomarkers are assessed in central facilities by
expert personnel blinded to the assigned treatment.
2. Intraoperative adverse events assessment: arterial hypo-
tension and hypertension, bradycardia and tachycardia,
osmotics and hyperventilation requirements [21].
3. Brain relaxation is assessed at dural opening, by the
neurosurgeon, blinded to the study group, using a 4-point
brain relaxation score [22,23]:
a) Relaxed brain.
b) Mild brain swelling, acceptable.
c) Moderate brain swelling, no therapy required.
d) Severe swelling, requiring treatment.
4. Post-operative adverse events assessment as seizures,
cough, shivering, agitation, cerebral haematoma and
post-operative pain.
5. Evaluation of patient's satisfaction through the filling of
the The Iowa Satisfaction with Anaesthesia Scale (ISAS, table
2[24]) 24 hours after surgery.
6. Evaluation of the costs of the three strategies.
Baseline characteristics of the patient (including demo-
graphics, medical history, physical exam, vital signs and
serial lab tests, ASA, Body Mass Index (BMI), planned
intracranial surgery) and all the variables registered during
and after the neurosurgery as haemodynamic parameters
(arterial pressure and heart rate), diuresis, body tempera-
ture, arterial saturation, blood gas analysis, end-tidal con-
centrations of anaesthetic vapour, oxygen, and carbon
dioxide, intraoperative and post-operative adverse events,
are recorded on a Case Report Form (CRF). Data collec-
tion ends 24 hours after the end of surgery.
A CRF, software based, has been develop and distributed
to the centers. Data are inputted at each centre and are
sent in an encrypted format to the coordinating centre for
storage in a central database and for statistical analysis. A
Table 2: The Iowa Satisfaction with Anaesthesia Scale (ISAS)
I threw up or felt like throwing up Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I would want to have the same anaesthetic again Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I itched Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I felt relaxed Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I felt pain Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I felt safe Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I was too cold or hot Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I was satisfied with my anaesthetic care Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I felt pain during surgery Disagree very much
Disagree moderately
Disagree slightly
Agree slightlyTrials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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monitoring program, according to GCP rules, has been
planned. It includes a central monitoring activity for effi-
cacy and safety and an on-site monitoring. Central and on
site monitoring activity are carried out by Mario Negri
Institute's experienced personnel and includes CRFs
reviewing in term of completeness and accuracy, errors
and omissions. All corrections are entered on data query
forms that are sent to the Investigator. On-site monitoring
consists in at least four visits for each participating site: a)
an initiation visit before starting the recruitment, b) a visit
after the third randomized patient, c) a visit after 15
recruited patients and d) a close-out visit. During this visit
the clinical monitor reviews on site all CRF and written
informed consents. Accuracy of the key data is verified
reviewing the source documents filed at the Investigator's
site and the clinical records.
An International Data and Safety Monitoring Board
(DSMB) guarantee the patients' safety during the study.
Serious adverse events (SAEs) are collected on the CRF
and evaluated by the DSMB. Investigators are required to
report to the Coordinating Centre all the SAEs suspected
to be related to the study medications within 24 hours
from their occurrence.
Fourteen Italian neuroanaesthesia departments have
agreed to participate to the study. These centers have been
selected on the basis of participation to previous multi-
center studies coordinated by San Gerardo Neurointen-
sive Care, Monza. These multicenter studies are Neurolink
[25], a survey on head injury in 28 Italian Neurosurgical
Hospitals (1997), Neurolink Domestic (on more than
1600 severely head injured patients, recruited from 1997
– still ongoing), BrainIT [26] (coordination of the Italian
centers, project supported by the EU framework V (EEC
Project:QLG3-2002-01160) http://www.brainit.org),
ESAnet (data collection in subarachnoid haemorrhage
patients in 23 Neurosurgical Departments [27]).
A web blog http://neuromorfeo.ning.com/ has been
developed for facilitating the communication between the
participating centers.
Statistical Analysis
This trial has the objective to evaluate if IR, as well as IF, is
equivalent to ER. As described previously, this objective
will be addressed by evaluation of the interval required to
reach an Aldrete score ≥ 9. To test for equivalence two
comparisons are planned:
1. IR vs. ER,
2. IF vs. ER.
The difference between the groups has been estimated on
a clinical judgment basis.
The estimate for the mean value and the standard devia-
tion of each group integrates also information from the
limited published literature.
Having a mean duration of the neurosurgical procedures
in the enrolling centers (and this information is available
because we did monitor > 100 neurosurgical procedures
in the 14 centers) of >300 minutes, for both the compari-
sons, it has been estimated that plausible equivalence lim-
its for the mean difference in the time to reach an Aldrete
score ≥ 9 range from ± 3 minutes with pooled standard
deviation equal to 7.
This evaluation comes from:
￿ The need of a rapid emergence from anaesthesia to
allow a quick neurological examination at the end of
procedure. Nevertheless this emergence is not instan-
taneous because prolonged administration of anesthe-
siological drugs (> 300 minutes) and their
pharmacokinetic properties requires variable interval
from their discontinuation to obtain an Aldrete score
≥ 9. This score considers many items as motor activity,
adequate respiration, normal circulation and periph-
eral perfusion and recover of consciousness. For reach-
ing the maximum values (9–10) the patient have to be
completely awake, with normal circulation and respi-
ratory, and be cooperative. On a pure clinical judg-
ment, ± 180 seconds, after > 300 minutes of
anaesthesia are a very short period. Based on a pure
clinical judgment this interval is extremely reasonable.
￿ The evaluation that this value is less than 1% of the
total surgical duration.
We selected an equivalence design because these differ-
ences aren't clinically significant and in our opinion the
Agree moderately
Agree very much
I felt good Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
I hurt Disagree very much
Disagree moderately
Disagree slightly
Agree slightly
Agree moderately
Agree very much
Table 2: The Iowa Satisfaction with Anaesthesia Scale (ISAS) Trials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
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strategies, according the primary endpoint, are similar.
Differences between the strategies will be evaluated ana-
lyzing multiple secondary endpoints.
The study assumes a 12–18 months of patients' enrol-
ment, a 10% drop-out rate and a overall significance level
≤ 0.05, taking into account that each comparison will be
tested at the significance level = 0.025.
A study sample size of 411 patients (137 in each group) is
estimated, since it will provide at least a power ≥ 84% to
reject the equivalence hypothesis. Sample size calculation
has been performed applying a two-group t-test of equiv-
alence in means performed with the statistical package
Nquery Advisor 6.01.
The intention to treat (ITT) population, consisting of all
randomized patients originally allocated to therapy spe-
cific anaesthesia arm at the time of randomization will be
used for the efficacy analysis. In addition a per protocol
(PP) analysis will be performed on the efficacy endpoint.
If the results of the two approaches will be somehow con-
troversial, the PP analysis will be regarded as the definitive
one being in the context of an equivalence trial. The pri-
mary efficacy outcome of the study is the time to reach an
Aldrete score ≥ 9. The conclusion that IR as well as IF are
equivalent to ER will be drawn if the lower limit of the
one-sided 95% interval around the mean difference is
greater than -3 minutes and the upper limit of the one-
sided 95% confidence interval around the mean differ-
ence is lower than 3 minutes. [28-30] Differences between
the two randomized groups will be analyzed by means of
analysis of variance or by a non-parametric approach if
distributional assumptions are not satisfied. Any clinically
significant imbalance between the randomized groups
will be considered for use as covariates. Secondary and
other efficacy outcomes of the study will be analyzed
using the same statistical methodology adopted for the
primary efficacy outcome. Safety analysis will be carried
out using the ITT population to allow a benefit/risk assess-
ment within the same study population.
Results
The first patient has been recruited on December 4, 2007.
In the following 6 months, all the centers have obtained
local IRB approval and the initiation visit. To date (4th,
December 2008) 314 patients have been enrolled in the
study. The enrolment should be completed during the sec-
ond quarter of 2009.
Discussion
NeuroMorfeo trial has been designed and initiated in the
context of an absence of evidence about the "best" anaes-
thetic strategy for supratentorial elective neurosurgical
procedures. Several studies have compared intravenous
with volatile-based neuroanaesthesia without conclusive
results in favour of one of the two strategies. Clinical
research is usually based on the concept of developing
new therapeutic strategies able to demonstrate a better
efficacy compared with those available, testing a null
hypothesis. Under certain circumstances, however, it may
be inappropriate to plan a trial around a null hypothesis.
The NeuroMorfeo study is a model case. Knowing that
several studies have tried to demonstrate a superiority of
one anaesthesiological strategy without conclusive results,
we decided to plan a study based on an equivalence
design and that is the innovative part of this protocol.
Some conditions have to be satisfied before choosing an
equivalence design. First, the treatment under considera-
tion exhibits therapeutic non-inferiority to the active con-
trol, that means in our field that no evidence about the
best anaesthesiological practice in elective neurosurgery is
available. Moreover, the tested treatment could offer
ancillary, even important, advantages in safety, tolerabil-
ity, cost, or convenience. These all are the relevant aspects
that this study is going to investigate.
An ideal neuroanesthesia should maintain an appropriate
cerebral oxygen supply and stable systemic haemody-
namic as well as rapid emergence time to allow a quick
neurological examination at the end of procedure.
This is the main reason for choosing the Aldrete score as
first, simple, measurable, endpoint. The Aldrete score is
the principal score used in literature to evaluate the post
anaesthesia awakening.
Secondary end points have no less importance than the
first one. This research will allow exploring many aspects
of modern neuroanaesthesia, as secondary endpoints. In
fact, we will compare these strategies in terms of neu-
rovegetative activation (haemodynamic stability, essay of
biomarkers of stress, cardiac autonomic function), intra-
operative and post-operative adverse events, state of brain
relaxation, patient's satisfaction and costs of the three
strategies.
To minimize bias in assessing the treatment effects, we
adopted a PROBE design: all the evaluation of haemody-
namic stability, biomarkers of stress, cardiac autonomic
function, surgical field and post-operative adverse events
are done by personnel blinded to the assigned treatment.
The design and formulation of this protocol will enable us
to reach a conclusion about the "best" elective neurosur-
gical anaesthesiological strategy.
Competing interests
The authors declare that they have no competing interests.Trials 2009, 10:19 http://www.trialsjournal.com/content/10/1/19
Page 9 of 10
(page number not for citation purposes)
Authors' contributions
GC, principal investigator, is responsible for coordinating
the NeuroMorfeo study. All authors contributed to the
design of the study and to draft the manuscript, and
approved the final version. SB is responsible for statistics
and data analysis. All authors will participate in interpre-
tation of results.
Appendix
Inclusion and exclusion criteria
Inclusion criteria
- patient scheduled for elective intracranial surgery under
general anaesthesia for a supratentorial mass lesion;
- physical state, evaluated with the ASA (American Society
of Anaesthesiologists, http://www.asahq.org/clinical/
physicalstatus.htm) classification I (normal healthy
patient), II (patient with mild systemic disease), or III
(patient with severe systemic disease);
- age 18–75 years;
- normal preoperative level of consciousness, i.e. Glasgow
Coma Scale (GCS) equal to 15;
- no clinical signs of intracranial hypertension.
Exclusion criteria
- Severe cardiovascular pathology, as uncontrolled arterial
hypertension and documented reduced coronary reserve;
- Renal or liver disease precluding the use of either anaes-
thetic technique;
- Pregnancy;
- Known allergies to any anaesthetic agent;
- Reduced preoperative level of consciousness, i.e. Glas-
gow Coma Scale (GCS) < 15;
- Body weight greater than 120 kg;
- History of drug abuse or psychiatric conditions;
- Documented disturbance of the hypothalamic region;
- Refusal to sign consent form;
- Participation in other clinical trials in the last 2 months;
- Planned awakening in ICU, due to the location and/or
size of the lesion, postoperative sedation and postopera-
tive mechanical ventilation requirements.
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